Insiders Trades
10x Genomics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 25 Feb 2025.
10x Genomics, Inc.: what insiders have been doing
Every trade that managers of 10x Genomics, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Pleasanton, United States. It was founded in 2012. From 18 October 2025 to 18 October 2026, the disclosure feed for 10x Genomics, Inc. logged 72 filings by 17 insiders.
There is no open-market purchase to report; the filings show 48 sales worth €13.4M by 6 insiders. The totals exclude 6 filings filed without an amount. Biggest ticket of the year: €1.7M, sold by Taich Adam and made public on 11 September 2026 (0.018% of market cap).
For context, the typical company on the same exchange (median of 5,813 companies) published 19 filings over the same period, against 72 filings here. Looking back to 2021, when coverage begins, insiders filed 3 purchases and 148 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 642.8 m USD and net income at -43.5 m USD.
Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
293
Thresholds
n/a
Buy Volume
€436,657
3 ops. · all time
Sell Volume
€24M
148 ops. · all time
Who traded when
BuySaleSerge Saxonov24 sales
Adam Taich9 sales
Shehnaaz Suliman9 sales
Hindson Benjamin J.8 sales
John R. Stuelpnagel5 sales
Teichmann Sarah A.3 sales
+1 other insider
Since the insiders bought
- +90.0%Entry US$11.65 · Close at T+365 US$22.13
- +16.2%Entry US$47.33 · Close at T+365 US$55.01
- +16.2%Entry US$47.33 · Close at T+365 US$55.01
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate 10x Genomics, Inc. Buy (bullish), based on 15 analysts. Average price target: US$77.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,342 of 24,148 companies
33.9
score / 100
Value38
Quality30
FCF yld1.4%
Earn yld-0.5%
EV/EBITDA·
ROE-9.4%
Gross mgn69%
Net mgn-6.8%
Debt/EBITDA21.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$72.39
Analyst consensus
15 analystsBuy
US$50.00Target US$77.00(+6%)US$110.00
Income statement
RevenueUS$642.8M
Gross profitUS$443.9M69% margin
EBITDAUS$3.9M1% margin
Net income-US$43.5M-12.2% margin
Valuation
PER (forward)944.2x
P/Book11.4x
Beta1.99
Balance sheet & cash
Market capUS$9.4B
Total debtUS$84.4M
Free Cash FlowUS$130.1M
Debt / Equity10%
Profitability & ownership
ROE-9.4%
ROA-5.0%
% insiders1.4%
% institutions117.2%
Last declaration on 24 September 2026
Declarations293 total
292 shares@ US$78.19590.0002% mcap3.8% of flowClass A Common StockSEC:0001610717-26-000422:0
2,000 shares@ US$79.61950.0014% mcap1.5% of flowClass A Common StockSEC:0001610717-26-000421:1
2,800 shares@ US$82.3650.0020% mcap2.2% of flowClass A Common StockSEC:0001610717-26-000421:4
614 shares@ US$79.51140.0004% mcap8.1% of flowClass A Common StockSEC:0001610717-26-000422:1
1,325 shares@ US$80.81640.0010% mcap17.8% of flowClass A Common StockSEC:0001610717-26-000422:2
2,270 shares@ US$81.66990.0016% mcap30.8% of flowClass A Common StockSEC:0001610717-26-000422:3
1,000 shares@ US$78.22840.0007% mcap0.7% of flowClass A Common StockSEC:0001610717-26-000421:0
9,300 shares@ US$80.90330.0067% mcap7.1% of flowClass A Common StockSEC:0001610717-26-000421:2
9,900 shares@ US$81.82540.0072% mcap7.7% of flowClass A Common StockSEC:0001610717-26-000421:3
1,222 shares@ US$82.27680.0009% mcap16.7% of flowClass A Common StockSEC:0001610717-26-000422:4
5,723 shares@ US$79.100.0040% mcap58.3% of flowClass A CommonSEC144:0001968582-26-001003
1,206 shares@ US$63.67740.0007% mcap1.2% of flowClass A Common StockSEC:0001610717-26-000414:0
13,754 shares@ US$65.25740.0079% mcap14.4% of flowClass A Common StockSEC:0001610717-26-000414:2
31,428 shares@ US$64.30970.018% mcap32.3% of flowClass A Common StockSEC:0001610717-26-000414:1
46,388 shares@ US$64.57430.026% mcap100.0% of flowCommonSEC144:0001950047-26-009250
6,174 shares@ US$62.60660.0034% mcap4.3% of flowClass A Common StockSEC:0001610717-26-000405:2
7,012 shares@ US$60.65790.0037% mcap4.7% of flowClass A Common StockSEC:0001610717-26-000405:0
6,814 shares@ US$62.10820.0037% mcap4.7% of flowClass A Common StockSEC:0001610717-26-000405:1
100 shares0Class A Common StockSEC:0001610717-26-000396:0
20,000 shares@ US$61.75230.011% mcap13.8% of flowClass A commonSEC144:0001957799-26-000170
3,500 shares@ US$63.02290.0019% mcap2.0% of flowClass A Common StockSEC:0001610717-26-000393:0
6,494 shares@ US$63.97680.0036% mcap3.9% of flowClass A Common StockSEC:0001610717-26-000393:1
492 shares@ US$64.74650.0003% mcap0.3% of flowClass A Common StockSEC:0001610717-26-000393:2
35,486 shares@ US$62.18380.019% mcap100.0% of flowClass A CommonSEC144:0001968582-26-000886
561 shares@ US$62.72590.0003% mcap5.7% of flowClass A Common StockSEC:0001610717-26-000389:0
25 of 293 declarations
About 10x Genomics, Inc.
10x Genomics, Inc. is a U.S.-based life-science tools company listed on the NASDAQ under the ticker TXG, with headquarters in Pleasanton, California, United States. For French, Belgian, and Swiss investors, the company sits in an attractive niche of the healthcare and research-tools universe: it provides technologies that help scientists study biology at the resolution of individual cells and within the spatial context of tissue. Founded in 2012 by Serge Saxonov and Ben Hindson, 10x Genomics has become one of the most recognized brands in single-cell and spatial biology, especially in academic and translational research settings. ([10xgenomics.com](https://www.10xgenomics.com/company/?utm_source=openai))
The company’s business model is built around instruments, consumables, reagents, software, and workflows used to profile cells and tissues for research purposes. Its core platforms are Chromium for single-cell analysis, Visium for spatial transcriptomics, and Xenium for in situ analysis. These products are designed to generate high-resolution biological data for fields such as oncology, immunology, neuroscience, and developmental biology. In practical terms, this gives 10x Genomics exposure to the research and discovery spending cycle rather than to routine clinical diagnostics, which is an important point for investors assessing demand volatility and the pace of adoption. ([10xgenomics.com](https://www.10xgenomics.com/company/?utm_source=openai))
Read moreShow less
From a competitive standpoint, 10x Genomics has built a strong reputation around data quality, workflow integration, and a broad scientific ecosystem. The company highlights more than 10,000 publications, a large installed base of instruments, and a global footprint spanning the United States, Europe, and Asia, including locations in the Netherlands, Taiwan, China, and Singapore. This international presence supports commercial reach and helps the company serve major research institutions worldwide. ([10xgenomics.com](https://www.10xgenomics.com/company/?utm_source=openai))
Recent news has centered on product innovation and portfolio expansion. In 2024, 10x Genomics launched major new products across all three platforms, including Chromium GEM-X, Visium HD, and Xenium Prime 5K. In its February 2025 earnings release, the company reported full-year 2024 revenue of $610.8 million and cash and marketable securities of $393.4 million at year-end, while also noting a challenging macro backdrop. It also announced the Billion Cells Project with the Chan Zuckerberg Initiative and Ultima Genomics, underscoring its strategic role in building large-scale biological datasets and advancing AI-enabled biology. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1770787/000177078725000011/txg-fy2024earningsreleasee.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
